Literature DB >> 20447386

Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism.

Angélica López-Izquierdo1, Daniela Ponce-Balbuena, Tania Ferrer, Aldo A Rodríguez-Menchaca, José A Sánchez-Chapula.   

Abstract

Thiopental is a well-known intravenous barbiturate anesthetic with important cardiac side effects. The actions of thiopental on the transmembrane ionic currents that determine the resting potential and action potential duration in cardiomyocytes have been studied widely. We aimed at elucidating the characteristics and mechanism of inhibition by thiopental on members of the subfamily of inward rectifying Kir2.x (Kir2.1, 2.2 and 2.3), Kir1.1 and Kir6.2/SUR2A channels. These inward rectifier potassium channels were transfected in HEK-293 cells and macroscopic currents were recorded in the whole-cell and inside-out configurations of the patch-clamp technique. Thiopental inhibited Kir2.1, Kir2.2, Kir2.3, Kir1.1 and Kir6.2/SUR2A currents with similar potency; in whole-cell experiments 30 microM thiopental decreased Kir2.1, Kir2.2, Kir2.3 and Kir1.1 currents to 55+/-6, 39+/-8, 42+/-5 and 49+/-5% at -120 mV, respectively. Point mutations on Kir2.3 (I213L) or Kir2.1 (L222I) did not modify the potency of block. Thiopental inhibited all Kir channels in a concentration-dependent and voltage-independent manner. Also, the time course of thiopental inhibition was slow (T(1/2) approximately 4 min) and independent of external or internal drug application. However, in the presence of PIP(2), inhibition by thiopental on Kir2.1 was significantly decreased. Thiopental at clinically relevant concentrations significantly inhibited all Kir channels evaluated in this work. The reduction of thiopental effects during PIP(2) treatment suggests that thiopental inhibition on Kir2.1 channels is related to channel-PIP(2) interaction. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447386     DOI: 10.1016/j.ejphar.2010.04.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133.

Authors:  Hao-Ran Wang; Meng Wu; Haibo Yu; Shunyou Long; Amy Stevens; Darren W Engers; Henry Sackin; J Scott Daniels; Eric S Dawson; Corey R Hopkins; Craig W Lindsley; Min Li; Owen B McManus
Journal:  ACS Chem Biol       Date:  2011-06-13       Impact factor: 5.100

2.  Inhibition of inwardly rectifying Kir2.x channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP2 interference.

Authors:  Daniel Scherer; Benedikt Schworm; Claudia Seyler; Panagiotis Xynogalos; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-02       Impact factor: 3.000

Review 3.  Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.

Authors:  Daniel R Swale; Sujay V Kharade; Jerod S Denton
Journal:  Curr Opin Pharmacol       Date:  2013-11-26       Impact factor: 5.547

4.  Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2/SUR2A channels.

Authors:  Daniela Ponce-Balbuena; Aldo A Rodríguez-Menchaca; Angélica López-Izquierdo; Tania Ferrer; Harley T Kurata; Colin G Nichols; José A Sánchez-Chapula
Journal:  Mol Pharmacol       Date:  2012-07-31       Impact factor: 4.436

5.  Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action.

Authors:  Nadine Vonderlin; Fathima Fischer; Edgar Zitron; Claudia Seyler; Daniel Scherer; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

6.  Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion; statins as a test case.

Authors:  Joana Real; Caroline Miranda; Charlotta S Olofsson; Paul A Smith
Journal:  Endocrinol Diabetes Metab       Date:  2018-03-30

7.  Tamoxifen inhibition of kv7.2/kv7.3 channels.

Authors:  Tania Ferrer; Ivan Arael Aréchiga-Figueroa; Mark S Shapiro; Martin Tristani-Firouzi; José A Sanchez-Chapula
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.